ClinicalTrials.gg
RecruitingNCT06769425HS-10502Updated Jun 24, 2025

HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

A Phase 1 interventional study of HS-10502 + NHA and HS-10502 + HS-20093 in Recurrent Ovarian Cancer, HER2-negative and Advanced Breast Cancer, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-24.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
157
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing apatinib in Ovarian Neoplasms — 6 open to participants now, 6 under way, 1 of them phase 3. apatinib · Ovarian Neoplasms.

Planned enrollment
4th of 22
157 · median 59
Started
2025
with 1 other
Phase 1
2 of 22
1 open now
Registered
21st of 22
by date
Lead sponsor
1 of 22
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Among the 22 studies testing apatinib in Ovarian Neoplasms, this one is the 4th largest by planned enrollment, is one of 2 that started in 2025, is one of 2 in phase 1, and was the 21st registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

6 of the 22 studies testing apatinib in Ovarian Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

About apatinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing apatinib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.

Read the detailed description

This is a phase I, multicenter, open-label clinical study to evaluate the safety, tolerability, PK, and efficacy of oral HS-10502 combination treatment in subjects with advanced solid tumors. The study will be divided into phase Ia (dose escalation) and phase Ib (dose expansion). The dose-escalation study will be conducted to evaluate the safety, tolerability, PK profile, and efficacy, as well as to determine the maximum tolerable dosage (MTD) or maximum applicable dose (MAD) of HS-10502 in combination with other antitumor agents (Enzalutamide, Rezvilutamide,Abiraterone,HS-20093,Apatinib,HS-20089,Platinum,Bevacizumab,nab-paclitaxel,Docetaxel, Irinotecan) The subsequent dose expansion study will select appropriate target populations (7 cohorts of recurrent ovarian cancer, HER2-negative advanced breast cancer, TNBC, advanced prostate cancer , advanced gastric cancer and HRD positive advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer) based on the data obtained in the phase Ia study, and determine the recommended phase II dose (RP2D) for each target population.

Safety evaluation will be performed for all the subjects in each cycle of therapy (3 weeks or 2 weeks) until Cycle 16, and then once every 6 weeks, until 30 days or 90 days after the last dose. The PK characteristics of HS-10502 will be evaluated during screening period and study treatment. Efficacy evaluation will be performed once every 6 weeks after C1D1 until objective disease progression or withdrawal from the study. As the disease progresses, survival follow-up will be performed every 12 weeks from the last dose.

03

Conditions studied

  • Recurrent Ovarian Cancer
  • HER2-negative
  • Advanced Breast Cancer
  • TNBC
  • Advanced Prostate Cancer
  • Advanced Gastric Cancer

Keywords

  • Poly(ADP-ribose) polymerase-1 inhibitor
  • HS-10502
  • ovarian cancer
  • breast cancer
  • TNBC
  • prostate cancer
  • gastric cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged 18 years or older (≥18 years).
  • Patients diagnosed with confirmed advanced solid tumors.
  • Subjects have at least one target lesion as assessed per the 1.1.
  • Performance Status (ECOG PS) score of 0 to 1 and no deterioration within 2 weeks before the first dose.
  • Have a of at least 12 weeks.
  • Female subjects of are willing to take appropriate measures and should not breastfeed from signing the until 6 months after the last dose; male subjects must agree to use barrier contraception (i.e. condoms) from signing the informed consent to 6 months after the last dose.
  • Female subjects must have a negative pregnancy test within 7 days prior to the first dose (for subjects with tumor related abnormal elevation of human chorionic gonadotropin [HCG], an ultrasound of uterus and appendages should be performed within 7 days prior to the first dose to rule out pregnancy), or demonstrate no risk for pregnancy.
  • Subject must be voluntarily enrolled in this clinical trial, be able to understand the study procedures and to sign written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Have received or is currently receiving the following treatment: PARPi/B7-H4/B7-H3-targeted therapies;
  • Have received or is currently receiving the following treatment: PARPi/B7-H4/B7-H3-targeted therapies;
  • Have received any of cytotoxic chemotherapy drugs, drugs, anti-tumor traditional Chinese medicines or other anti-tumor drugs within 14 days prior to the first dose of study drug; or need to continue these drugs during the study.
  • Presence of Grade ≥ 2 toxicities as per due to prior anti-tumor therapy.
  • Presence of pleural/abdominal effusion requiring clinical intervention.
  • Known history of other primary .
  • Evidence of and/or cancerous meningitis
  • Inadequate bone marrow reserve or hepatic/renal functions.
  • Cardiological examination abnormality.
  • Severe, uncontrolled or active cardiovascular disorders.
  • Serious or poorly controlled diabetes.
  • Serious or poorly controlled hypertension.
  • bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose of study treatment.
  • Serious infections within 4 weeks prior to the first dose.
  • Have received systemic therapy for more than 7 days within 28 days prior to the first dose study treatment, or require chronic (≥ 7 days) use of systemic glucocorticoids during the study, or have other acquired, congenital immunodeficiency disorders, or a history of organ transplantation.
  • Presence of active infectious diseases such as , , tuberculosis, syphilis, or infection, etc.
  • Current hepatic encephalopathy, hepatorenal syndrome, or Class B or more severe cirrhosis.
  • Any moderate or severe lung diseases that may interfere with the detection and treatment of drug-related pulmonary toxicity or may seriously affect respiratory function.
  • History of severe neurological or psychiatric disorder.
  • Pregnant or breast-feeding women or women who intend to become pregnant during the study.
  • Attenuated within 4 weeks prior to the first dose.
  • Subjects with disease that is active or is likely to recur.
  • Subjects with gastrointestinal fistula, visceral fistula, gastrointestinal perforation, or abdominal abscess, or with symptoms/signs of intestinal obstruction within 6 months prior to the first dose of study drug.
  • Subjects unlikely to comply with study procedures, restrictions and requirement as determined by the investigator.
  • Subjects with any condition that jeopardizes the safety of the patient or interferes with the assessment of the study, as judged by the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
157 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Advanced prostate cancer

    Drug: HS-10502 + NHA

  • Experimental
    Cohort 2

    Advanced prostate cancer or solid tumor

    Drug: HS-10502 + HS-20093

  • Experimental
    Cohort 3

    Advanced HER2-negative breast cancer or recurrent ovarian cancer

    Drug: HS-10502+ Apatinib

  • Experimental
    Cohort 4

    Recurrent ovarian cancer

    Drug: HS-10502 + HS-20089

  • Experimental
    Cohort 5

    Platinum-sensitive recurrent ovarian cancer

    Drug: HS-10502 + Platinum + Bevacizumab

  • Experimental
    Cohort 6

    Advanced gastric cancer or solid tumor

    Drug: HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan

  • Experimental
    Cohort 7

    HRD positive advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer

    Drug: HS-10502 + Bevacizumab

Interventions

  • DrugHS-10502 + NHA

    HS-10502 + NHA

  • DrugHS-10502 + HS-20093

    Drug page: Risvutatug rezetecan

    HS-10502 + HS-20093

  • DrugHS-10502+ Apatinib

    Drug page: Apatinib

    HS-10502+ Apatinib

  • DrugHS-10502 + HS-20089

    Drug page: Mocertatug rezetecan

    HS-10502 + HS-20089

  • DrugHS-10502 + Platinum + Bevacizumab

    Drug pages: Platinum Compounds · Bevacizumab

    HS-10502 + Platinum + Bevacizumab

  • DrugHS-10502 + nab-paclitaxel or Docetaxel or Irinotecan

    HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan

  • DrugHS-10502 + Bevacizumab

    Drug page: Bevacizumab

    HS-10502 + Bevacizumab

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) of HS-10502(Stage 1:Dose escalating stage)

    MTD is defined as the previous dose level at which 2 or more out of 2-6 subjects experienced a DLT.

    Time frame: Cycle 1 (21 days)

  2. Maximum applicable dose (MAD) of HS-10502(Stage 1:Dose escalating stage)

    MAD is defined as follows: a) based on PK data, it is anticipated that at this dose level, the dose-exposure plateau has been reached, b) based on existing safety data, it is judged that dose escalation following this dose level will have a large safety risk or subject intolerance, or c) based on the PK-PD model, it suggested that the optimal target concentration of safety and efficacy has been explored.

    Time frame: Cycle 1 (21days)

  3. Efficacy of HS-10502: Objective response rate (ORR)(Stage 2: Dose expansion stage)

    ORR is defined as the proportion of participants with BOR of confirmed CR or confirmed PR per RECIST v1.1 (applicable for all solid tumors except prostate cancer) or per RECIST v1.1 and PCWG3 (for prostate cancer only).

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

Secondary outcomes

  1. Incidence and severity of treatment-emergent adverse events

    Assessed by number and severity of adverse events as evaluated according to NCI CTCAE v5.0.

    Time frame: From Cycle 1 Day 1 (C1D1) until 21 days after the final dose. A cycle is 21days.

  2. PK parameters: The maximum observed concentration (Cmax) of HS-10502

    Defines as the maximum plasma drug concentration of HS-10502

    Time frame: Cycle 1 Day 1 (each cycle is 21 days)

  3. PK parameters: time to Cmax (Tmax) of HS-10502

    Time of maximum observed concentration of HS-10502.

    Time frame: Cycle 1 Day 1 (each cycle is 21 days)

  4. PK parameters: area under the concentration-time curve from time 0 to time t of last measurable concentration (AUC0-t) of HS-10502.

    Area under the curve from the time of dosing to the time of the last measurable (positive) concentration.

    Time frame: Cycle 1 Day 1 (each cycle is 21 days)

  5. PK parameters: Maximum plasma concentration at steady state (Css, max) of HS-10502

    Defines as the maximum plasma drug concentration at steady state of HS-10502.

    Time frame: Cycle 2 Day 1 (each cycle is 21 days)

  6. PK parameters: time to Css, max (Tss, max) of HS-10502

    Time of maximum observed concentration at steady state of HS-10502.

    Time frame: Cycle 2 Day 1 (each cycle is 21 days)

  7. PK parameters: Minimum plasma concentration at steady state (Css, min) of HS-10502

    Minimum plasma drug concentration at steady state of HS-10502.

    Time frame: Cycle 2 Day 1 (each cycle is 21 days)

  8. PK parameters: Area under the plasma concentration-time curve over a dosing interval at steady state (AUCss) of HS-10502

    The partial area from dosing time to dosing time plus dosing interval of HS-10502.

    Time frame: Cycle 2 Day 1 (each cycle is 21days)

  9. Efficacy of HS-10502: ORR

    ORR is defined as the proportion of participants with BOR of confirmed CR or confirmed PR per RECIST v1.1 (applicable for all solid tumors except prostate cancer) or per RECIST v1.1 and PCWG3 (for prostate cancer only).

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

  10. Efficacy of HS-10502: disease control rate (DCR)

    The disease control was defined as the percentage of patients who have a best overall response (confirmed CR, PR, or stable disease for at least 5 weeks) per RECIST v1.1 (applicable for all solid tumors except prostate cancer) or per RECIST v1.1 and PCWG3 (for prostate cancer only).

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

  11. Efficacy of HS-10502: duration of response (DoR)

    DoR only applies to participants whose best overall response is CR or PR based on assessment per RECIST v1.1 (applicable for all solid tumors except prostate cancer) or per RECIST v1.1 and PCWG3 (for prostate cancer only). The start date is the date of first documented response of CR or PR (i.e. the start date of observed response, not the date when response was confirmed), and the end date is defined as the date of the first documented progression or death due to underlying cancer.

    Time frame: From the date of CR, PR until the date of disease progression or withdrawal from study, approximately 2 years

  12. Efficacy of HS-10502: progression free survival (PFS) (applicable for all solid tumors except prostate cancer)

    PFS is defined as the time from the date of randomization or first dose (if randomization is not needed) to the date of the first documented progression or death due to any cause. PFS will be assessed per RECIST v1.1.

    Time frame: From the date of randomization or first dose (if randomization is not needed) until the date of disease progression or withdrawal from study, approximately 2 years.

  13. Efficacy of HS-10502: radiographic progression free survival (rPFS) (for prostate cancer only)

    rPFS is defined as the time from the date of randomization or first dose (if randomization is not needed) to the date of the first documented progression or death due to any cause. rPFS will be assessed per RECIST v1.1 (soft tissue) and PCWG3 (bone).

    Time frame: From the date of randomization or first dose (if randomization is not needed) until the date of disease progression or withdrawal from study, approximately 2 years.

  14. Efficacy of HS-10502: ORR evaluated by RECIST v1.1 and GCIG CA-125 (for ovarian cancer only)

    For ovarian cancer, ORR is defined as the proportion of participants with BOR of confirmed CR or confirmed PR per both RECIST v1.1 and GCIG CA-125 criteria.

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

  15. Efficacy of HS-10502: overall survival (OS)

    OS is defined as the time from the date of randomization or first dose (if randomization is not needed) to the date of death due to any cause. For each participant who is not known to have died as of the cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.

    Time frame: From the date of randomization or first dose (if randomization is not needed) until the documentation of death from any cause, approximately 4 years

  16. Efficacy of HS-10502: Proportion of subjects with CA-125 decreased by ≥ 50% from baseline (for ovarian cancer only)

    The percentage of subjects (ovarian cancer only) with a reduction of at least 50% from baseline in CA-125 levels.

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

  17. Efficacy of HS-10502: PSA50 response rate (for prostate cancer only)

    PSA50 response rate is defined as the proportion of subjects with a PSA nadir of ≤ 50% of baseline PSA level confirmed by serial PSA assessments (at least 3 weeks apart) after the start of the study.

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

  18. Efficacy of HS-10502: Time to PSA progression (for prostate cancer only)

    Time to PSA progression is defined as the time from the first dose to PSA progression based on PCWG3 criteria.

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2026, 12 months after the start.

Of 209 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 12 months is below that.

Counting every sponsor, half of 379 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2025
First posted
Jan 10, 2025
StartActual
May 7, 2025
Primary completionEst.
May 7, 2026
CompletionEst.
Aug 31, 2026
Last update
Jun 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06769425
Responsible party
Sponsor
First posted
Jan 10, 2025
Start date
May 7, 2025
Primary completion
May 7, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Jun 24, 2025

Study contacts

Xi Yan
Contact
yanx1@hspharm.com
18721195312

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Risvutatug rezetecan · Apatinib · Mocertatug rezetecan · Platinum Compounds · Bevacizumab

Start the discussion